First Trust Nasdaq Pharmaceuticals ETF
FTXH
18 hedge funds and large institutions have $16M invested in First Trust Nasdaq Pharmaceuticals ETF in 2021 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
33% more capital invested
Capital invested by funds: $12M → $16M (+$4.02M)
8.65% more ownership
Funds ownership: 62.02% → 70.67% (+8.6%)
5% less funds holding
Funds holding: 19 → 18 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$1.95M |
| 2 |
IAN
Integrated Advisors Network
Dallas,
Texas
|
+$718K |
| 3 |
LJAC
L.J. Altfest & Co
New York
|
+$607K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$512K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$252K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
-$262K |
| 2 |
LPL Financial
San Diego,
California
|
-$197K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$44.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$35.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$34K |
FTXH Hedge Fund Activity: Q2 2021 in Review
18 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2021, worth a combined $16M — up 33% from $12M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of FTXH and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was International Assets Investment Management, adding an estimated $1.95M. The largest seller was Flagship Harbor Advisors, exiting entirely with an estimated $262K sold.
- 18 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2021, down from 19 in Q1 2021.
- Funds reported $16M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2021, up 33% quarter-over-quarter.
- 2 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2021 and 3 closed out, a net change of -1 holder.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2021 was International Assets Investment Management, an estimated $1.95M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2021 was Flagship Harbor Advisors, an estimated $262K sold.
Based on aggregated 13F filings for Q2 2021.